Cencora Set to Announce Q1 Earnings on February 4th
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 03 2026
0mins
Should l Buy COR?
Source: seekingalpha
- Earnings Announcement: Cencora (COR) is set to release its Q1 2023 earnings on February 4th before market open, with consensus EPS estimates at $4.04, reflecting an 8.3% year-over-year growth, which could further solidify its growth position in the industry.
- Revenue Expectations: The revenue is projected to reach $86.17 billion, marking a 5.7% year-over-year increase, indicating the company's ongoing expansion in the high-growth specialty services sector, potentially attracting more investor interest.
- Historical Performance: Over the past two years, Cencora has achieved a 100% accuracy rate in EPS estimates and a 75% accuracy rate in revenue estimates, showcasing its strong forecasting capabilities and bolstering market confidence in its future performance.
- Estimate Revision Dynamics: In the last three months, EPS estimates have seen three upward revisions and four downward adjustments, while revenue estimates experienced two upward and three downward revisions, reflecting mixed market sentiment regarding Cencora's future performance, which may influence investor decisions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy COR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on COR
Wall Street analysts forecast COR stock price to rise
9 Analyst Rating
8 Buy
1 Hold
0 Sell
Strong Buy
Current: 317.660
Low
400.00
Averages
415.38
High
440.00
Current: 317.660
Low
400.00
Averages
415.38
High
440.00
About COR
Cencora, Inc. is a global pharmaceutical sourcing and distribution services company. The Company helps both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. The Company operates through two segments: U.S. Healthcare Solutions and International Healthcare Solutions. The U.S. Healthcare Solutions segment distributes a comprehensive offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, long-term care and alternate site pharmacies, and other customers. The International Healthcare Solutions segment consists of businesses that focus on international pharmaceutical wholesale and related service operations and global commercialization services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cencora to Release Q2 Fiscal 2026 Results on May 6, 2026
- Earnings Release Schedule: Cencora plans to announce its Q2 Fiscal 2026 results on May 6, 2026, prior to the opening of trading, reflecting the company's ongoing growth in the global pharmaceutical solutions sector.
- Conference Call Details: The company will host a conference call at 8:30 AM ET on the same day, featuring CEO Robert P. Mauch and CFO James F. Cleary, who are expected to discuss performance and future outlook in depth.
- Webcast Information: The call will be webcast live on Cencora's website, with users encouraged to log in 10 minutes early to ensure smooth participation, enhancing investor engagement.
- Replay Availability: A replay of the call will be available on the website approximately one hour after the meeting concludes and will remain accessible for one year, ensuring that investors who could not attend live can still access key information.
See More
Cencora Acquires EyeSouth's Retina Business for $1.1B
- Acquisition Overview: Cencora (COR) has signed an agreement to acquire EyeSouth Partners' retina business for $1.1 billion through its eye care subsidiary, Retina Consultants of America, marking a significant move in its ongoing M&A strategy aimed at strengthening its market position in the ophthalmology sector.
- Financial Impact Analysis: The company anticipates that the transaction, after adjusting for financing costs, will slightly boost its adjusted diluted earnings per share (EPS) in the first twelve months post-closure, indicating confidence in its future financial performance.
- Accelerated M&A Activity: Cencora has ramped up its M&A activities recently, with this acquisition following a $3.5 billion merger agreement with Covetrus involving its MWI Animal Health unit, highlighting its aggressive expansion strategy within the healthcare industry.
- Future Outlook: While Cencora reaffirmed its fiscal 2026 outlook, it noted that the deal is not expected to close within the current fiscal year, reflecting a cautious approach to integration amid its aggressive acquisition strategy.
See More
Active ETFs Outperform Passive Ones, with These Leading the Way
Active vs. Passive ETFs: Active ETFs, which are managed by fund managers and not tied to specific indices, have seen a significant increase in fees and performance compared to traditional passive ETFs, with active funds outperforming passive ones in recent years.
Capital Group Dividend Value ETF (CGDV): CGDV aims to provide dividend income exceeding the average yield on U.S. stocks, focusing on established domestic firms and diversifying across various sectors, with a strong emphasis on stability and income generation.
T. Rowe Price Capital Appreciation ETF (TCAF): TCAF combines well-known stocks with lesser-known companies, targeting growth at reasonable prices, and aims to deliver strong returns with lower risk compared to the broader market.
Dan Ives' AI Revolution ETF (IVES): This ETF, managed by a well-known technology analyst, focuses on AI-related companies and offers investors access to a curated selection of stocks in the tech space, appealing to those interested in the growing AI sector.
See More
Cencora Reaffirms Fiscal 2026 Financial Guidance Amid $1.1 Billion Acquisition
- Acquisition Agreement: Cencora has signed a definitive agreement to acquire EyeSouth Partners' retina business for $1.1 billion, which will integrate EyeSouth's retina physicians into Cencora's Retina Consultants of America, thereby enhancing its market position in ophthalmology.
- Financial Impact: Cencora expects the acquisition to be slightly accretive to its adjusted diluted EPS in the first twelve months post-transaction, although the deal's completion is not included in its fiscal 2026 financial guidance.
- Strategic Collaboration: The partnership with EyeSouth will enhance access to innovative treatments, as EyeSouth's physicians will leverage RCA's clinical trial and research resources to further improve patient care quality.
- Advisory Team: BofA Securities and Citi are serving as financial advisors to Cencora, while Sidley Austin LLP acts as legal counsel; Jefferies LLC and Kirkland & Ellis LLP are advising EyeSouth, ensuring a smooth transaction process.
See More
CENCORA Acquires EyeSouth Partners' Retina Division for $1.1 Billion
Acquisition Announcement: Cencora has announced its intention to acquire EyeSouth Partners' retina business for $1.1 billion.
Strategic Move: This acquisition is part of Cencora's strategy to expand its portfolio in the healthcare sector, particularly in eye care services.
See More
Cencora Inc Shares Show Oversold Signal
- Oversold Indicator: Cencora Inc (Ticker: COR) hit an RSI of 29.9 during Wednesday's trading, indicating an oversold condition with shares dropping to a low of $318.12, suggesting that the recent heavy selling pressure may be waning, thus providing potential buying opportunities for investors.
- Market Comparison: Compared to the current RSI of 36.3 for the S&P 500 ETF (SPY), COR's oversold status may attract bullish investors looking for entry points to capitalize on a potential rebound in the stock price.
- Price Fluctuation: COR's 52-week low stands at $262.73, while the high is $377.54, with the last trade at $325.18, indicating the stock's performance within this range, which could influence investor decisions moving forward.
- Investor Sentiment: As COR shares enter oversold territory, investors may reassess their strategies and consider buying in anticipation of a price recovery, potentially profiting from future market rebounds.
See More
Cencora to Release Q2 Fiscal 2026 Results on May 6, 2026
- Earnings Release Schedule: Cencora plans to announce its Q2 Fiscal 2026 results on May 6, 2026, prior to the opening of trading, reflecting the company's ongoing growth in the global pharmaceutical solutions sector.
- Conference Call Details: The company will host a conference call at 8:30 AM ET on the same day, featuring CEO Robert P. Mauch and CFO James F. Cleary, who are expected to discuss performance and future outlook in depth.
- Webcast Information: The call will be webcast live on Cencora's website, with users encouraged to log in 10 minutes early to ensure smooth participation, enhancing investor engagement.
- Replay Availability: A replay of the call will be available on the website approximately one hour after the meeting concludes and will remain accessible for one year, ensuring that investors who could not attend live can still access key information.
See More
Cencora Acquires EyeSouth's Retina Business for $1.1B
- Acquisition Overview: Cencora (COR) has signed an agreement to acquire EyeSouth Partners' retina business for $1.1 billion through its eye care subsidiary, Retina Consultants of America, marking a significant move in its ongoing M&A strategy aimed at strengthening its market position in the ophthalmology sector.
- Financial Impact Analysis: The company anticipates that the transaction, after adjusting for financing costs, will slightly boost its adjusted diluted earnings per share (EPS) in the first twelve months post-closure, indicating confidence in its future financial performance.
- Accelerated M&A Activity: Cencora has ramped up its M&A activities recently, with this acquisition following a $3.5 billion merger agreement with Covetrus involving its MWI Animal Health unit, highlighting its aggressive expansion strategy within the healthcare industry.
- Future Outlook: While Cencora reaffirmed its fiscal 2026 outlook, it noted that the deal is not expected to close within the current fiscal year, reflecting a cautious approach to integration amid its aggressive acquisition strategy.
See More
Active ETFs Outperform Passive Ones, with These Leading the Way
Active vs. Passive ETFs: Active ETFs, which are managed by fund managers and not tied to specific indices, have seen a significant increase in fees and performance compared to traditional passive ETFs, with active funds outperforming passive ones in recent years.
Capital Group Dividend Value ETF (CGDV): CGDV aims to provide dividend income exceeding the average yield on U.S. stocks, focusing on established domestic firms and diversifying across various sectors, with a strong emphasis on stability and income generation.
T. Rowe Price Capital Appreciation ETF (TCAF): TCAF combines well-known stocks with lesser-known companies, targeting growth at reasonable prices, and aims to deliver strong returns with lower risk compared to the broader market.
Dan Ives' AI Revolution ETF (IVES): This ETF, managed by a well-known technology analyst, focuses on AI-related companies and offers investors access to a curated selection of stocks in the tech space, appealing to those interested in the growing AI sector.
See More
Cencora Reaffirms Fiscal 2026 Financial Guidance Amid $1.1 Billion Acquisition
- Acquisition Agreement: Cencora has signed a definitive agreement to acquire EyeSouth Partners' retina business for $1.1 billion, which will integrate EyeSouth's retina physicians into Cencora's Retina Consultants of America, thereby enhancing its market position in ophthalmology.
- Financial Impact: Cencora expects the acquisition to be slightly accretive to its adjusted diluted EPS in the first twelve months post-transaction, although the deal's completion is not included in its fiscal 2026 financial guidance.
- Strategic Collaboration: The partnership with EyeSouth will enhance access to innovative treatments, as EyeSouth's physicians will leverage RCA's clinical trial and research resources to further improve patient care quality.
- Advisory Team: BofA Securities and Citi are serving as financial advisors to Cencora, while Sidley Austin LLP acts as legal counsel; Jefferies LLC and Kirkland & Ellis LLP are advising EyeSouth, ensuring a smooth transaction process.
See More
CENCORA Acquires EyeSouth Partners' Retina Division for $1.1 Billion
Acquisition Announcement: Cencora has announced its intention to acquire EyeSouth Partners' retina business for $1.1 billion.
Strategic Move: This acquisition is part of Cencora's strategy to expand its portfolio in the healthcare sector, particularly in eye care services.
See More
Cencora Inc Shares Show Oversold Signal
- Oversold Indicator: Cencora Inc (Ticker: COR) hit an RSI of 29.9 during Wednesday's trading, indicating an oversold condition with shares dropping to a low of $318.12, suggesting that the recent heavy selling pressure may be waning, thus providing potential buying opportunities for investors.
- Market Comparison: Compared to the current RSI of 36.3 for the S&P 500 ETF (SPY), COR's oversold status may attract bullish investors looking for entry points to capitalize on a potential rebound in the stock price.
- Price Fluctuation: COR's 52-week low stands at $262.73, while the high is $377.54, with the last trade at $325.18, indicating the stock's performance within this range, which could influence investor decisions moving forward.
- Investor Sentiment: As COR shares enter oversold territory, investors may reassess their strategies and consider buying in anticipation of a price recovery, potentially profiting from future market rebounds.
See More
